Trending...
- Make Innovation Matter: Support H.R.1's R&D Expensing Relief for American Small Businesses
- Google AI Quietly Corrects the Record on Republic of Aquitaine's Legal Sovereignty
- Chicago: Mayor Brandon Johnson Announces 2026 Budget Engagement Roundtables
MADRID - illiNews -- OncoBeta®, a leading medical device company specialising in innovative epidermal radioisotope therapies, today announced Hospital Universitario 12 de Octubre, in Madrid, has treated its first patient with Rhenium-SCT® (skin cancer therapy) – and is expected to continue offering this therapy for patients with non-melanoma skin cancers (NMSCs).
Rhenium skin cancer therapy is an advanced radionuclide therapy technology that offers a painless,*1,2 single-session,†1-3 non-invasive‡1 treatment without disfiguring scarring.1,4 Treatment with Rhenium-SCT employs a superficial application of a paste containing β-emitting particles directly to the NMSC lesion, targeting cancer cells without the need for surgery.1,4
Shannon D. Brown III, CCO at OncoBeta, says, "With rates of NMSC increasing globally, we feel it's vitally important that new treatment options are offered to patients. Surgical intervention continues to be the most common treatment, but it can lead to disappointing results. Rhenium skin cancer therapy addresses many patients' desires for a non-surgical alternative – with simple application directly to the lesion, treatment time generally ranges 45 to 180 mins, which means patients can continue with their lives with very little disruption."
New cases of NMSCs in Spain are expected to almost double from 2022-2050 according to latest figures by the International Agency of Research on Cancer as part of the World Health Organization,5 making Mardrid an important location for this innovative NMSC treatment option.
"Rhenium-SCT has long been accessible to patients across Europe. This new clinic in Spain marks a significant milestone in expanding access to this innovative treatment for non-melanoma skin cancer patients," Mr Brown explains.
Dr Gerhard Dahlhoff, Medical Director at OncoBeta, says, "Rhenium-SCT allows for a targeted and non-invasive treatment of NMSCs without damaging adjacent healthy tissue. It offers a patient-friendly treatment alternative and we are delighted to have another medical facility offering Rhenium-SCT to those suffering with NMSCs".
More on illi News
___
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.1 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.1,4
The Rhenium-SCT is a painless,*1,2 single session,†1-3 non-invasive‡1 therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.1,4,6 The Rhenium-SCT utilizes the radioisotope rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalized therapy that is only applied to the area needed to treat without affecting the healthy tissue.4,6 The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (basal cell carcinomas and squamous cell carcinomas) can be treated using the Rhenium-SCT in one single session. †1-4 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.1,6,7
About OncoBeta®
OncoBeta® with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
Find out more about the Rhenium-SCT at www.oncobeta.com
More on illi News
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain during procedure.1,2
†Complete tumour regression in 98.5% of lesions treated.3
‡A treatment is considered non-invasive when no cut or break in the skin is created.8
References
Rhenium skin cancer therapy is an advanced radionuclide therapy technology that offers a painless,*1,2 single-session,†1-3 non-invasive‡1 treatment without disfiguring scarring.1,4 Treatment with Rhenium-SCT employs a superficial application of a paste containing β-emitting particles directly to the NMSC lesion, targeting cancer cells without the need for surgery.1,4
Shannon D. Brown III, CCO at OncoBeta, says, "With rates of NMSC increasing globally, we feel it's vitally important that new treatment options are offered to patients. Surgical intervention continues to be the most common treatment, but it can lead to disappointing results. Rhenium skin cancer therapy addresses many patients' desires for a non-surgical alternative – with simple application directly to the lesion, treatment time generally ranges 45 to 180 mins, which means patients can continue with their lives with very little disruption."
New cases of NMSCs in Spain are expected to almost double from 2022-2050 according to latest figures by the International Agency of Research on Cancer as part of the World Health Organization,5 making Mardrid an important location for this innovative NMSC treatment option.
"Rhenium-SCT has long been accessible to patients across Europe. This new clinic in Spain marks a significant milestone in expanding access to this innovative treatment for non-melanoma skin cancer patients," Mr Brown explains.
Dr Gerhard Dahlhoff, Medical Director at OncoBeta, says, "Rhenium-SCT allows for a targeted and non-invasive treatment of NMSCs without damaging adjacent healthy tissue. It offers a patient-friendly treatment alternative and we are delighted to have another medical facility offering Rhenium-SCT to those suffering with NMSCs".
More on illi News
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
- The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
- Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
___
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.1 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.1,4
The Rhenium-SCT is a painless,*1,2 single session,†1-3 non-invasive‡1 therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.1,4,6 The Rhenium-SCT utilizes the radioisotope rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalized therapy that is only applied to the area needed to treat without affecting the healthy tissue.4,6 The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (basal cell carcinomas and squamous cell carcinomas) can be treated using the Rhenium-SCT in one single session. †1-4 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.1,6,7
About OncoBeta®
OncoBeta® with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
Find out more about the Rhenium-SCT at www.oncobeta.com
More on illi News
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
- Digital Watchdog Launches New myDW Cloud Services
- Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
- Drone Light Shows Emerge as the New Standard in Live Event Entertainment
- Lore Link is Here to Help Organize Your Game
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain during procedure.1,2
†Complete tumour regression in 98.5% of lesions treated.3
‡A treatment is considered non-invasive when no cut or break in the skin is created.8
References
- Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48: 1511–1521.
- Cipriani C, et al. J Dermatol Treat. 2022;33(2):969–975. Epub 22 Jul 2020.
- Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.
- Tietze JK, et al. Clin Nucl Med. 2023;48:869–76.
- Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.
- Cipriani C, et al. International J Nucl Med. 2017; July:114–112.
- Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745–749.
- Australian Therapeutic Goods Administration. Acronym and glossary of terms. Available at: https://www.tga.gov.au/resources/acronyms-and-glossary-terms. (Accessed June 2024).
Source: OncoBeta GmbH
0 Comments
Latest on illi News
- ALIVE and KICKING: LAUGHTER NEVER GETS OLD has its World Premiere July 11-20 in St. Charles, IL
- AAR to announce fourth quarter fiscal year 2025 results on July 16, 2025
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- New Dad Battles Leukemia and Wins!
- Kefir Comes to NASCAR as Lifeway Foods Races into Hometown Weekend with Driver Josh Bilicki at The Loop 110
- Recession-Proof Startups: What Business Plans Investors Are Actually Funding in 2025
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- City of Chicago Releases Annual Comprehensive Financial Report for Fiscal Year 2024
- Indies United is pleased to present our July 2025 book releases
- Endurance Warranty Earns 2025 Buyer's Choice Awards from ConsumerAffairs Through Verified Customer Reviews
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Naperville: Structure Fire in the 1600 Block of Country Lakes Drive
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- Bak Brothers, Inc. Expands Exterior Remodeling Services to La Grange, IL
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
- The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence